Enhanced Genomics
PrivateLast Round
Series A
Sep 16, 2025
Est. Valuation
$31.18M
Total Funding Raised
$40.41M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Enhanced Genomics operates in Healthcare & Life Sciences and is based in Cambridge. Its latest recorded funding round was a Series A round in September 2025.
Enhanced Genomics is a biotechnology company that develops a 3D multi-omics platform to map genome folding and identify therapeutic targets for drug discovery.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine, Healthcare Analytics
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Enhanced Genomics Comparables
Compare Enhanced Genomics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nucleome Therapeutics | 85% | |
| Genomics | 77% | |
| Arima Genomics | 77% |
For institutional investors. Book with your work email.
Enhanced Genomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 16, 2025 | ||||
| Series A | Oct 20, 2022 | ||||
| Seed | Mar 26, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Enhanced Genomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Start Codon | Seed |
| BGF | Series A |
| Meltwind Advisory | Series A |
| Bioqube Ventures | Series A, Seed |
| Parkwalk Advisors | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 82% MoM.
- Sep 16, 2025
$19M round led by Parkwalk Advisors and BGF.
For institutional investors. Book with your work email.
Enhanced Genomics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Enhanced Genomics's valuation, stock price, and market status.
Is Enhanced Genomics a public or private company?
Enhanced Genomics is a private company.
What is the current stock price of Enhanced Genomics?
Enhanced Genomics is a private company, so its shares have no public market price. Caplight tracks Enhanced Genomics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Enhanced Genomics worth (valuation)?
Enhanced Genomics's valuation is estimated at $31.2M based on funding round data.
Can I buy Enhanced Genomics stock?
Enhanced Genomics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Enhanced Genomics's last funding round?
Enhanced Genomics's most recent funding round was Series A on September 16, 2025.
Who are the main investors in Enhanced Genomics?
Key investors in Enhanced Genomics include BGF, Parkwalk Advisors.
Will Enhanced Genomics IPO soon?
No public IPO plans have been announced for Enhanced Genomics.
How can I track Enhanced Genomics secondary market activity?
Caplight tracks bids, offers, and trades in Enhanced Genomics's shares on secondary markets.